In this issue:
Bone marrow density checks prevent major fractures in men on ADT
HRQoL with front-line lenvatinib/pembrolizumab for RCC
Neoadjuvant nintedanib does not improve response rate in MIBC
10-year results from DART 01/05: adjuvant ADT for localised prostate cancer
Neoadjuvant atezolizumab plus chemotherapy for MIBC
Longitudinal ctDNA changes may be prognostic for treatment response in UC
Carboplatin AUC10 a less toxic option for good-prognosis metastatic seminoma
Putative biomarkers of benefit with pembrolizumab in advanced UC
Delayed surgery after progression may be safe for early-stage prostate cancer
Prior BCG does not impact outcomes after ICI in advanced UC
Please login below to download this issue (PDF)